ResMed Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
ResMed
Visual. Strategic. Downloadable.
ResMed’s BCG Matrix snapshot reveals where its sleep and respiratory care portfolio may sit across Stars, Cash Cows, Question Marks, and Dogs—highlighting growth drivers like cloud-connected devices and stable revenue from CPAP consumables. This brief view teases product positioning and strategic implications; purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and a ready-to-use Word + Excel package to guide investment, R&D, and allocation decisions.
Stars
AirSense 11 and Next-Gen CPAP Platforms
The AirSense 11 remains ResMed's flagship growth driver, capturing a dominant position in a global sleep apnea market projected at $8.5B in 2025 with penetration under 40%, and ResMed holding over 50% share by late 2025.
Its AI-driven algorithms and seamless integration with ResMed myAir and patient-engagement apps have made it the go-to for new setups and upgrades, supporting a device ASP near $1,100 and recurring cloud revenue growth of ~18% YoY in 2024–25.
The platform benefits from Philips' prolonged U.S. gap, driving higher unit volumes (up ~12% YoY in FY2025) and reinforcing ResMed's Star placement in the BCG matrix.
Connected Health Ecosystem and AirView Platform
ResMed’s digital health ecosystem—centered on AirView and myAir—monitors over 34 million patients globally by early 2026, creating high retention and adherence via connected devices and care workflows.
As a Star in the BCG matrix, it delivers a data-driven moat—real-world sleep and respiratory datasets boost outcomes and pricing power—while requiring ongoing AI and cloud R&D spending (hundreds of millions annually) to scale.
Advanced Mask Systems and Interface Innovations
ResMed’s newer mask lines, led by AirFit F40 and the F30i Comfort fabric (launched 2024), are driving double-digit revenue growth—about 15–22% CAGR in the Americas and 12–18% internationally in 2024–2025—by tackling the main barrier to PAP therapy: patient comfort.
These masks rank as high-growth stars in the BCG matrix, capturing new users and increasing system penetration via aggressive marketing and channel expansion, contributing roughly $200–350M ARR to mask revenue in 2025.
However, the rapid product refresh and phased global rollouts demand sizable OPEX: ResMed invested an estimated $40–60M in 2024–2025 for R&D, regulatory, and promotional spend specific to these lines, pressuring margins despite strong top-line gains.
High-Growth International Markets (India and China)
ResMed treats India and China as Stars: double-digit sleep apnea device market growth (India ~18% CAGR 2023–25; China ~12%); AirSense 11 launched in India in 2025 to capture first-to-market share.
The company is investing >$50m in local distribution and physician training programs through 2026 to convert current penetration (India ~5%, China ~18%) into long-term dominance.
- India launch: AirSense 11, 2025
- Growth: India ~18% CAGR, China ~12%
- Penetration: India ~5%, China ~18%
- Investment: >$50m to 2026
Smart Comfort AI-Enabled Therapy Tools
The late 2025 FDA clearance and early‑2026 launch of Smart Comfort, an AI‑enabled medical device for personalized CPAP settings, positions it as a Star in ResMed’s BCG matrix given projected market CAGR of ~9% for digital therapeutics and an estimated $400–600m first‑year revenue potential in premium markets.
It blends medical hardware and advanced software, targets personalized medicine and adherence (current CPAP nonadherence ~30–40%), needs heavy promotion and beta testing, and could raise ResMed’s sleep‑apnea share by 3–5 percentage points if uptake hits 10–15% of eligible patients.
- FDA clearance: Dec 2025
- Launch: Q1 2026
- First‑year revenue est.: $400–600m
- CPAP nonadherence: 30–40%
- Uptake target: 10–15% of eligible patients
- Market CAGR (digital therapeutics): ~9%
ResMed surges: AirSense dominance, masks boom & Smart Comfort to add $400–600M in 2026
AirSense 11 and new masks are Stars: >50% ResMed share, AirSense ASP ~$1,100, cloud rev +18% YoY, unit growth +12% FY2025; masks CAGR 15–22% Americas, 12–18% intl, masks ARR $200–350M (2025); India/China investments >$50M, India penetration ~5%, China ~18%; Smart Comfort FDA Dec 2025, launch Q1 2026, first‑year rev est. $400–600M.
| Metric | Value |
|---|---|
| ResMed share | >50% |
| AirSense ASP | $1,100 |
| Cloud rev growth | ~18% YoY |
| Masks ARR (2025) | $200–350M |
| Smart Comfort 1st‑yr | $400–600M |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of ResMed’s units with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page ResMed BCG Matrix placing each business unit in a quadrant for quick strategy decisions
Cash Cows
CPAP Masks and Consumable Accessories
The replacement market for masks, cushions, and tubing is ResMed’s primary cash engine, driven by a global installed base of ~8 million cloud-connected devices as of Dec 2025 and recurring purchases every 3–6 months.
Operating in a mature segment where ResMed holds a leading market share (~40% global masks), it needs low incremental capex versus device R&D.
High-margin consumables generated ~45% of FY2025 product gross profit, funding R&D and the dividend increase announced in Nov 2025.
Legacy AirSense 10 Device Series
AirSense 10 remains a Cash Cow for ResMed, selling ~1.2M units globally in 2024 and generating roughly $450M in annual device revenue, as many markets favor lower-cost, proven CPAP over flagship AirSense 11 features.
The line has fully amortized R&D; uses established distributors, needs <5% of historical marketing spend, and delivers steady gross margins near 55%, funding ResMed’s digital-health bets like myAir and Somnowell.
Home Ventilation and Respiratory Care Devices
ResMed’s home ventilators and bilevel devices for COPD and other chronic respiratory diseases hold a dominant, high-share position in a mature market; the global home ventilation market was valued at about $4.8B in 2024 with annual growth near 3–4%, lower than sleep apnea.
These life-sustaining devices show steady gross margins (ResMed reported ~58% device gross margin in FY2025) and low marketing spend due to strong clinical adoption and high switching costs.
Brightree and MatrixCare SaaS Solutions
Brightree and MatrixCare SaaS generate high-margin recurring revenue, with Residential Care Software growth stabilized at mid-single digits (~5–6% CAGR by Q1 2026) and gross margins above 60%, supplying steady cash from a dominant US HME (home medical equipment) share ~40%.
ResMed milks these units to fund digital health R&D and M&A, contributing ~15% of FY2025 free cash flow earmarked for newer initiatives.
- Mid-single digit growth: ~5–6% CAGR (to Q1 2026)
- Gross margin: >60%
- US HME market share: ~40%
- Contribution to FY2025 free cash flow: ~15%
North American Distribution and Logistics Network
ResMed’s mature North American distribution and logistics network acts as a Cash Cow by delivering a low-cost pathway to market across the U.S. and Canada, supporting steady cash flow for product launches and renewals.
The scale and automation of the network yield superior gross margins versus smaller peers; logistics efficiencies and volume purchasing pushed ResMed toward a 62% gross margin target by late 2025, boosting free cash generation.
Operational optimizations—warehouse consolidation, route densification, and vendor-managed inventory—cut per-unit fulfillment costs materially, preserving pricing power despite market pressure.
- Low-cost channel across U.S./Canada
- Scale-driven margin advantage vs smaller rivals
- 62% gross margin target reached by late 2025
- Warehouse consolidation & route densification reduced fulfillment unit costs
ResMed: Consumables & AirSense10 fuel recurring high‑margin cash flow
ResMed’s cash cows: consumables (masks/cushions/tubing) and AirSense 10 drive recurring high-margin revenue (~45% of FY2025 product gross profit; masks ~40% global share; ~8M cloud devices Dec 2025). Home ventilators and SaaS (Brightree/MatrixCare) add steady cash (home vent market ~$4.8B in 2024; SaaS >60% gross margin; ~15% of FY2025 FCF).
| Metric | Value |
|---|---|
| Cloud devices (Dec 2025) | ~8M |
| Masks global share | ~40% |
| Consumables profit share | ~45% |
| AirSense 10 units (2024) | ~1.2M |
| Home ventilation market (2024) | $4.8B |
| SaaS gross margin | >60% |
| FY2025 FCF from cash cows | ~15% |
Preview = Final Product
ResMed BCG Matrix
The file you're previewing is the final ResMed BCG Matrix you'll receive after purchase—no watermarks, no placeholders—just a professionally formatted, analysis-ready report built for strategic clarity. This preview matches the exact downloadable document delivered to your inbox, crafted with market-backed insights and ready for editing, printing, or presenting to stakeholders. Buy once and unlock the complete file immediately with no surprises or additional revisions required.
Dogs
Legacy Non-Connected CPAP Devices
Legacy non-cloud CPAPs are BCG Matrix Dogs: they hold single-digit market share in a shrinking legacy segment — ResMed reported devices without cloud connectivity fell >30% YoY in units through FY2025 — and deliver lower margins (estimated gross margin ~20% vs 45% for connected devices in 2024).
ResMed is actively phasing them out, reclaiming shelf space and cutting admin costs; management flagged discontinuation of specific legacy SKUs in H1 2025 to reallocate ~$40M annualized cost base toward digital services and remote-monitoring growth.
Underperforming International Niche Markets
Certain small international markets where ResMed (ticker RMD) has operated for years but failed to reach a top-three share are now classified as Dogs; these markets collectively generated under 3% of global revenue (~<$150m of FY2025 $5.1bn total revenue) and show single-digit CAGR. Regulatory complexity and low reimbursement levels push cost-to-serve above margins, with average gross margins in these markets ~15–20% vs corporate ~45%. In 2025–2026 ResMed is refocusing capital on high-opportunity markets and is likely to divest or sharply cut investment in these low-performance regions.
Redundant Software Modules from Past Acquisitions
As ResMed consolidates brands under one identity in 2025, legacy software modules from prior tuck-in buys show low market share (<2%) and sit in stagnant niches with <3% CAGR to 2030, misaligned with the 2030 platform strategy.
These modules cost ~US$18–25M/year in maintenance and support across R&D and hosting yet generate under US$4M revenue, making them cash traps that drain resources from core cloud and AI initiatives.
Standalone Diagnostic Tools without Ecosystem Integration
Older standalone diagnostic tools that lack AirView or myAir connectivity are losing relevance as integrated data becomes essential; ResMed reported in 2024 that connected-device revenue grew 18% while non-connected device unit sales fell ~12% year-over-year.
These products face pressure from sub-$200 low-cost devices and wearables (global sleep wearable shipments rose ~22% in 2024), leading to low market share and near-zero growth for standalone lines.
Given shrinking demand and higher unit costs, these SKUs are prime discontinuation candidates as ResMed doubles down on its connected-diagnostics strategy and platform monetization.
- Connected revenue +18% (2024)
- Non-connected unit sales -12% (2024)
- Wearable shipments +22% (2024)
- Low-cost devices <$200 pressure
Low-Margin Third-Party Distributed Products
Products ResMed distributes for third parties often sit in the Dog quadrant: low margins, no manufacturing control, and limited pricing power; these lines typically yield gross margins under 20% versus ResMed’s company-wide ~56% in FY2024 (ended Sep 30, 2024).
In 2025 ResMed is cutting these lower-value partnerships to redeploy capital toward high-margin, patented devices and digital care (Star and Question Mark segments), aiming to raise product mix margin by ~3–5 percentage points.
Minimizing distributed lines frees working capital and lowers inventory turns tied to third-party SKUs, supporting R&D and margin expansion in core respiratory and sleep therapy franchises.
- Distributed products: gross margin <20%
- ResMed FY2024 gross margin: ~56%
- 2025 target mix shift: +3–5 ppt product margin
- Capital freed: reallocated to R&D and patented devices
ResMed shutters non-cloud CPAPs, reallocates $40M to faster-growing connected devices
Legacy non-cloud CPAPs and select low-share intl markets are Dogs for ResMed: single-digit share, shrinking demand (non-connected units -12% in 2024), low margins (~15–25% vs company ~56% FY2024), and >$40M reallocated in H1 2025; plan: discontinue SKUs, cut distributed lines, and refocus on connected devices (connected revenue +18% in 2024).
| Metric | Dogs | Company |
|---|---|---|
| Non-connected unit growth (2024) | -12% | — |
| Connected revenue growth (2024) | +18% | — |
| Gross margin | 15–25% | ~56% FY2024 |
| Revenue from low-share markets | <$150M (≈3%) | $5.1B FY2025 |
| Annualized reallocation | ~$40M | — |
Question Marks
Residential Care Software (RCS) Expansion
While ResMed’s core Residential Care Software (RCS) is a Cash Cow, its expansion into home health and hospice is a Question Mark: US home health market grew ~6.8% CAGR 2019–2024 to $106B and hospice ~5.5% to $22B, but ResMed’s share in these segments is single-digit versus incumbents like PointClickCare and Netsmart.
ResMed invested ~$600M in software R&D and M&A in FY2024 and launched targeted offerings in 2023–24, yet its software revenue mix remains ~18% of total company sales, so scaling share will need sustained capital and execution.
NightOwl and Home Sleep Testing (HST)
The 2025 U.S. launch of NightOwl home sleep apnea test gives ResMed a high-growth diagnostic play; U.S. HST volume grew ~25% CAGR 2020–24 to ~2.4M tests in 2024, implying a >$600M addressable device market.
NightOwl is a Question Mark: home testing demand is exploding but ResMed faces dozens of tech entrants and VC-backed startups capturing share; market fragmentation raises customer-acquisition costs.
To become a Star ResMed must drive rapid primary-care adoption—if PCP referral share rises from ~10% to 30% within 18 months, revenue could scale to $200–300M by 2027; otherwise it remains a niche diagnostic asset.
AI-Driven Predictive Health Analytics
ResMed's AI-driven predictive health analytics leverages 20 billion nights of sleep data to detect risks like cardiovascular events, but remains in early development with minimal revenue and under 1% share of the broader medical AI market as of 2025.
Market potential is large—preventative care models could expand the addressable market to an estimated $60–80 billion for predictive diagnostics by 2030—yet the segment currently qualifies as a Question Mark in the BCG matrix due to low market share and high growth potential.
Scaling requires continued R&D and regulatory work; ResMed reported R&D spend of $367 million in FY2024 and will likely need similar or higher annual investment plus clinical trials to demonstrate outcomes and commercialize products.
GLP-1 Patient Engagement Programs
ResMed’s GLP-1 patient engagement program is a 2026 Question Mark: GLP-1 users show ~30–40% higher CPAP initiation in early pilots, but widespread weight-loss effects could cut OSA prevalence by an uncertain 10–30% over 3–5 years, making long-term market size unclear.
ResMed is funding doctor outreach and targeted marketing in 2025–26, risking up-front spend (~$20–50m) to win a cohort that may become a major growth driver or remain a niche.
- Early pilots: +30–40% CPAP starts
- Potential OSA reduction: 10–30% (3–5 yrs)
- Investment range: $20–50m (2025–26)
- Outcome: scale driver or niche
Wearable Integration and Consumer Sleep Tech
Integrating ResMed's medical-grade sleep data with consumer wearables like Apple Watch is a high-growth Question Mark: global wearable shipments hit 450 million units in 2024 and sleep-tracking users reached ~150 million, but ResMed's digital revenue was $1.1B in FY2024, showing nascent consumer reach.
The risk: tech giants control platforms and consumer prefs shift fast, so ResMed must choose heavy investment to lead the prosumer segment or let wearables become gateways for competitors into sleep care.
- Wearables: 450M shipments 2024, ~150M sleep users
- ResMed digital revenue: $1.1B FY2024
- Option A: invest to capture prosumer market
- Option B: partner/licence to avoid platform lockout
ResMed’s Growth Gambits: AI, NightOwl, GLP‑1 & wearables eye multi‑billion upside
ResMed’s Question Marks: home health/hospice (single-digit share; US markets $106B/$22B by 2024), NightOwl HST (2.4M tests 2024; >$600M device TAM), AI diagnostics (20B nights data; <1% med-AI share 2025), GLP-1 pilots (+30–40% CPAP starts; $20–50M 2025–26 spend), wearables (450M shipments 2024).
| Asset | 2024/25 metric |
|---|---|
| Home health/hospice | $106B/$22B; single-digit share |
| NightOwl HST | 2.4M tests; >$600M TAM |
| AI diagnostics | 20B nights; <1% market |
| GLP-1 program | +30–40% CPAP; $20–50M |
| Wearables | 450M ships; 150M sleep users |